Clinical trial NCT04693897 - References

Overactive Bladder Syndrome — Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and as a Urinary Biomarker

Citation(s)

•   Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A; Standardisation Sub-committee of the International Continence Society
  The standardisation of terminology of lower urinary tract function: report from the
•   Aizawa N, Homma Y, Igawa Y
  Effects of mirabegron, a novel ß3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin. Eur Urol. 2012 Dec;62(6):1165-73. doi: 10.1016/j.eururo
•   Aizawa N, Igawa Y, Nishizawa O, Wyndaele JJ
  Effects of CL316,243, a beta 3-adrenoceptor agonist, and intravesical prostaglandin E2 on the primary bladder afferent activity of the rat. Neurourol Urodyn. 2010 Jun;29(5):771-6. doi: 10.1002/nau.20826.
•   Andersson KE
  Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004 Jan;3(1):46-53. Review.
•   Cardozo L, Thorpe A, Warner J, Sidhu M
  The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder i
•   Chapple CR, Fianu-Jonsson A, Indig M, Khullar V, Rosa J, Scarpa RM, Mistry A, Wright DM, Bolodeoku J; STAR study group
  Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. Eur Urol. 2007 Oct;52(4):1195-203. Epu
•   Chen GD, Lin TL, Hu SW, Chen YC, Lin LY
  Prevalence and correlation of urinary incontinence and overactive bladder in Taiwanese women. Neurourol Urodyn. 2003;22(2):109-17.
•   Chen HL, Chen TC, Chang HM, Juan YS, Huang WH, Pan HF, Chang YC, Wu CM, Wang YL, Lee HY
  Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis. World J Urol. 20
•   Chuang YC, Fraser MO, Yu Y, Chancellor MB, de Groat WC, Yoshimura N
  The role of bladder afferent pathways in bladder hyperactivity induced by the intravesical administration of nerve growth factor. J Urol. 2001 Mar;165(3):975-9.
•   Ciftci S, Ozkurkcugil C, Yilmaz H, Ustuner M, Yavuz U, Yuksekkaya M, Cekmen MB
  Urinary nerve growth factor and a variable solifenacin dosage in patients with an overactive bladder. Int Urogynecol J. 2016 Feb;27(2):275-80. doi: 10.1007/s00192-015-2825-3.
•   Clemow DB, Steers WD, Tuttle JB
  Stretch-activated signaling of nerve growth factor secretion in bladder and vascular smooth muscle cells from hypertensive and hyperactive rats. J Cell Physiol. 2000 Jun;183(3):289-300.
•   Coyne KS, Sexton CC, Kopp ZS, Ebel-Bitoun C, Milsom I, Chapple C
  The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS. BJU Int. 2011 Nov;108(9):1459-71. doi: 10
•   Diamond P, Hassonah S, Alarab M, Lovatsis D, Drutz HP
  The prevalence of detrusor overactivity amongst patients with symptoms of overactive bladder: a retrospective cohort study. Int Urogynecol J. 2012 Nov;23(11):1577-80. doi: 10.1007/s00192-012-1781-4. E
•   Digesu GA, Khullar V, Cardozo L, Salvatore S
  Overactive bladder symptoms: do we need urodynamics? Neurourol Urodyn. 2003;22(2):105-8. Erratum in: Neurourol Urodyn. 2003;22(4):356.
•   Giarenis I, Mastoroudes H, Srikrishna S, Robinson D, Cardozo L
  Is there a difference between women with or without detrusor overactivity complaining of symptoms of overactive bladder? BJU Int. 2013 Aug;112(4):501-7. doi: 10.1111/j.1464-410X.2012.11652.x.
•   Hashim H, Abrams P
  Is the bladder a reliable witness for predicting detrusor overactivity? J Urol. 2006 Jan;175(1):191-4; discussion 194-5.
•   Hsiao SM, Chang TC, Wu WY, Chen CH, Yu HJ, Lin HH
  Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome. J Obstet Gynaecol Res. 2011 Aug;37(8):1084-91. doi: 10.1111/j.1
•   Hung MJ, Ho ES, Shen PS, Sun MJ, Lin AT, Chen GD; Taiwan OAB Club
  Urgency is the core symptom of female overactive bladder syndrome, as demonstrated by a statistical analysis. J Urol. 2006 Aug;176(2):636-40.
•   Igawa Y, Yamazaki Y, Takeda H, Hayakawa K, Akahane M, Ajisawa Y, Yoneyama T, Nishizawa O, Andersson KE
  Functional and molecular biological evidence for a possible beta3-adrenoceptor in the human detrusor muscle. Br J Pharmacol. 1999 Feb;126(3):819-25.
•   Jafarabadi M, Jafarabadi L, Shariat M, Rabie Salehi G, Haghollahi F, Rashidi BH
  Considering the prominent complaint as a guide in medical therapy for overactive bladder syndrome in women over 45 years. J Obstet Gynaecol Res. 2015 Jan;41(1):120-6. doi: 10
•   Jeong SJ, Lee SC, Jeong CW, Hong SK, Byun SS, Lee SE
  Clinical and urodynamic differences among women with overactive bladder according to the presence of detrusor overactivity. Int Urogynecol J. 2013 Feb;24(2):255-61. doi: 10.1007/s00192-012-1817-9. Epub
•   Kuo HC, Lee KS, Na Y, Sood R, Nakaji S, Kubota Y, Kuroishi K
  Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a ß3-adrenoceptor agonist, in patients with overactive bladder in Asia. N
•   Liu HT, Chancellor MB, Kuo HC
  Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. BJU Int. 2009 Jun;103(12):1668-72. doi: 10.1111/j.1464-410X.2009.08380.x. Epub 2009 Feb 11.
•   Liu HT, Kuo HC
  Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder. J Urol. 2008 Jun;179(6):2270-4. doi: 10.1016/j.juro.2008.01.146. Epub 2008 Apr 18.
•   Liu HT, Kuo HC
  Urinary nerve growth factor levels are elevated in patients with overactive bladder and do not significantly increase with bladder distention. Neurourol Urodyn. 2009;28(1):78-81. doi: 10.1002/nau.20599.
•   Luo D, Liu L, Han P, Wei Q, Shen H
  Solifenacin for overactive bladder: a systematic review and meta-analysis. Int Urogynecol J. 2012 Aug;23(8):983-91. doi: 10.1007/s00192-011-1641-7. Epub 2012 Feb 7. Review.
•   Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJ
  Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev. 2012 Jan 18;1:CD005429. doi: 10.1002/14651858.CD005429.pub2. Review.
•   Malone-Lee JG, Al-Buheissi S
  Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study. BJU Int. 2009 Apr;103(7):931-7. doi: 10.1111/j.1464-410X.2009.08361.x. Epub 2009 Mar 5.
•   Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ
  How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001 Jun;87(9):760-6. Erratum in: BJU Int 2001 Nov;88(7):807.
•   Mukerji G, Yiangou Y, Grogono J, Underwood J, Agarwal SK, Khullar V, Anand P
  Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. J Urol. 2006 Jul;176(1):367-73.
•   Nazir J, Kelleher C, Aballéa S, Maman K, Hakimi Z, Mankowski C, Odeyemi I
  Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta-analysi
•   Nitti VW, Rovner ES, Bavendam T
  Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity. BJU Int. 2010 May;105(9):1268-75. doi: 10.1111/j.1464-410X
•   Otsuka A, Shinbo H, Matsumoto R, Kurita Y, Ozono S
  Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium. Naunyn Schmiedebergs Arch Pharmacol. 2008 Jun;377(4-6):473-81. doi: 10.1007/s00210-008-0274-y. Epub 2008 Mar
•   Ouslander JG
  Management of overactive bladder. N Engl J Med. 2004 Feb 19;350(8):786-99. Review.
•   Sekido N, Hinotsu S, Kawai K, Shimazui T, Akaza H
  How many uncomplicated male and female overactive bladder patients reveal detrusor overactivity during urodynamic study? Int J Urol. 2006 Oct;13(10):1276-9.
•   Sheng W, Zhang H, Ruth KH
  Could urinary nerve growth factor be a biomarker for overactive bladder? A meta-analysis. Neurourol Urodyn. 2017 Sep;36(7):1703-1710. doi: 10.1002/nau.23210. Epub 2017 Jan 19. Review.
•   Speakman M, Khullar V, Mundy A, Odeyemi I, Bolodeoku J
  A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome. Curr Med Res Opin. 2008 Aug;24(8):2173-9. doi: 10.1185/03007990802234829. Ep
•   Steers WD, Kolbeck S, Creedon D, Tuttle JB
  Nerve growth factor in the urinary bladder of the adult regulates neuronal form and function. J Clin Invest. 1991 Nov;88(5):1709-15.
•   Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, Wein AJ
  Prevalence and burden of overactive bladder in the United States. World J Urol. 2003 May;20(6):327-36. Epub 2002 Nov 15.
•   Takeda M, Obara K, Mizusawa T, Tomita Y, Arai K, Tsutsui T, Hatano A, Takahashi K, Nomura S
  Evidence for beta3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J Phar
•   Tyagi P, Thomas CA, Yoshimura N, Chancellor MB
  Investigations into the presence of functional Beta1, Beta2 and Beta3-adrenoceptors in urothelium and detrusor of human bladder. Int Braz J Urol. 2009 Jan-Feb;35(1):76-83.
•   Vecchioli Scaldazza C, Morosetti C
  Comparison of Therapeutic Efficacy and Urodynamic Findings of Solifenacin Succinate versus Mirabegron in Women with Overactive Bladder Syndrome: Results of a Randomized Controlled Study. Urol Int. 2016;97(3):325-329. Ep
•   Yamaguchi O
  Beta3-adrenoceptors in human detrusor muscle. Urology. 2002 May;59(5 Suppl 1):25-9. Review.

To Explore the Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and Develop Its Urinary Biomarker

Details for clinical trial NCT04693897